PEG MGF Ireland | Buy Research-Grade PEGylated Mechano Growth Factor | ≥99% Purity

PEG MGF — PEGylated Mechano Growth Factor — is a synthetic polyethylene glycol-conjugated analogue of the mechano growth factor splice variant of insulin-like growth factor-1 and one of the most extensively characterised long-acting IGF-1 splice variant research compounds available to laboratories in Ireland — a PEGylated peptide corresponding to the unique C-terminal E-domain of the MGF splice variant of IGF-1 that activates distinct MGF-specific receptors and signalling pathways in skeletal muscle satellite cells, cardiomyocytes, and neural tissue to drive muscle progenitor cell activation, myoblast proliferation, tissue repair initiation, and cytoprotective biology through mechanisms distinct from and complementary to the canonical IGF-1 receptor pathway — with PEGylation of the native MGF E-domain peptide extending circulating half-life from minutes to days and enabling sustained tissue exposure not achievable with unconjugated MGF — making it an indispensable research tool for studying MGF-specific receptor pharmacology and signal transduction distinct from IGF-1R biology, mechano-sensitive IGF-1 splice variant regulation and muscle satellite cell activation, the role of the MGF E-domain peptide in muscle repair and regeneration initiation, PEGylation as a half-life extension strategy for labile splice variant peptides, cardiac and neural MGF biology and cytoprotective signalling, and the comparative pharmacology of MGF E-domain peptide versus full-length IGF-1 splice variants in the research context of tissue repair and growth factor biology. Researchers and institutions across Ireland can source verified, research-grade PEG MGF directly from our Irish peptide supply, with domestic-speed dispatch and complete batch documentation.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA) Included

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch to Ireland | Peptides Ireland Stock

What Is PEG MGF?

PEG MGF — PEGylated Mechano Growth Factor — is the polyethylene glycol-conjugated form of the MGF E-domain peptide, a synthetic 24-amino acid peptide corresponding to the unique C-terminal extension domain that distinguishes the mechano growth factor splice variant of IGF-1 from other IGF-1 splice variants including IGF-1Ea and IGF-1Eb. Mechano Growth Factor is produced in skeletal muscle, cardiac muscle, bone, and neural tissue through mechano-sensitive alternative splicing of the IGF-1 pre-mRNA — a splicing event triggered by mechanical loading, muscle damage, exercise, and tissue injury that inserts a 49-nucleotide sequence producing the MGF reading frame shift and generating the unique MGF E-domain peptide sequence absent from all other IGF-1 splice variants. This mechano-sensitive production distinguishes MGF from the systemic liver-derived IGF-1 axis — MGF represents a locally produced, mechanically regulated autocrine and paracrine tissue repair signal whose biology is architecturally distinct from the systemic endocrine IGF-1-IGF-1R axis.

The pharmacological research interest of the MGF E-domain peptide derives from its receptor pharmacology — the MGF C-terminal E-domain peptide activates biological responses in skeletal muscle satellite cells, cardiomyocytes, and neural tissue that are not fully recapitulated by IGF-1 acting through the canonical IGF-1R and that are not blocked by IGF-1R antagonists — establishing that the MGF E-domain engages receptor targets distinct from or in addition to the IGF-1R. Research has characterised MGF E-domain peptide-specific activation of satellite cell proliferation, myoblast activation, and muscle repair initiation biology through proposed MGF-specific receptor interactions that remain an active area of investigation — with evidence suggesting involvement of distinct membrane receptor complexes, integrin signalling, and IGF-1R-independent intracellular signalling pathways including ERK1/2 MAPK and calcineurin-NFAT pathways in MGF-stimulated satellite cell responses.

Native MGF E-domain peptide has an extremely short half-life in biological matrices — degraded rapidly by serum proteases with a circulating half-life estimated at under 5 minutes — severely limiting its utility as a research tool for in vivo studies and chronic tissue exposure paradigms. PEGylation — the covalent attachment of polyethylene glycol chains to the peptide — addresses this limitation by sterically shielding the MGF E-domain peptide from proteolytic degradation, reducing renal clearance through molecular weight increase, and dramatically extending circulating half-life to approximately 24–72 hours depending on PEG chain molecular weight and conjugation site. This PEG-mediated half-life extension transforms the MGF E-domain peptide from a research tool limited to acute in vitro applications into a compound enabling in vivo tissue exposure studies, chronic satellite cell activation research, and systemic tissue repair biology investigations not accessible with the native unconjugated peptide.

What Does PEG MGF Do in Research?

In controlled laboratory and pre-clinical settings, PEG MGF is studied across skeletal muscle satellite cell biology, MGF-specific receptor pharmacology, muscle repair and regeneration, cardiac MGF biology, neural cytoprotection, PEGylation pharmacokinetics, and comparative IGF-1 splice variant applications:

Skeletal Muscle Satellite Cell Activation and Proliferation Research

PEG MGF is the primary research tool for studying MGF E-domain peptide-driven satellite cell activation — the critical first step in skeletal muscle repair following mechanical damage or injury. Research has used PEG MGF to characterise satellite cell activation kinetics, proliferative burst magnitude, and myoblast commitment in primary satellite cell cultures and ex vivo muscle fibre preparations — examining the transition from quiescent Pax7+/MyoD- satellite cells to activated Pax7+/MyoD+ myoblasts following MGF E-domain peptide stimulation, the downstream myogenic regulatory factor expression changes including MyoD, Myf5, and myogenin upregulation, and how PEG MGF-driven satellite cell activation compares to mechanical loading-induced endogenous MGF production in its capacity to initiate the myogenic repair programme. These satellite cell biology studies have established PEG MGF as the reference long-acting MGF research tool for studying muscle progenitor cell activation biology.

MGF-Specific Receptor Pharmacology and IGF-1R-Independent Signalling Research

The MGF E-domain peptide activates satellite cell and myoblast responses that are not fully explained by IGF-1R engagement — making PEG MGF a research tool for characterising the IGF-1R-independent receptor pharmacology of the MGF C-terminal domain. Research has examined PEG MGF signalling in satellite cells and myoblasts in the presence of IGF-1R blocking antibodies and small molecule IGF-1R inhibitors — characterising the residual MGF E-domain peptide signalling that persists despite IGF-1R blockade and identifying the alternative receptor interactions mediating IGF-1R-independent MGF biology. Studies have characterised PEG MGF activation of ERK1/2 MAPK, PI3K-Akt, and calcineurin-NFAT pathways in satellite cells — examining how these signalling cascades downstream of MGF-specific receptor engagement drive satellite cell proliferation and myogenic differentiation commitment independently of canonical IGF-1R signalling.

Muscle Repair and Regeneration Biology Research

PEG MGF’s extended half-life enables in vivo muscle repair and regeneration studies not achievable with native MGF — making it a research tool for characterising the contribution of MGF E-domain biology to the full muscle repair programme following mechanical damage, eccentric injury, or freeze-crush injury in rodent models. Research has examined PEG MGF administration in muscle injury models — characterising satellite cell activation kinetics, myofibre regeneration rates, cross-sectional area recovery, fibrosis attenuation, and functional force recovery in PEG MGF-treated versus vehicle control muscles. These in vivo repair biology studies have established PEG MGF as a pharmacological tool for studying the causal contribution of sustained MGF E-domain signalling to muscle regeneration outcomes and characterised the temporal window of MGF-responsive satellite cell biology in the repair process.

Cardiac MGF Biology and Cardiomyocyte Cytoprotection Research

MGF E-domain peptide is expressed in cardiac muscle following ischaemic injury and mechanical stress — and PEG MGF activates cytoprotective responses in cardiomyocytes through anti-apoptotic and pro-survival signalling pathways. Research has used PEG MGF in cardiac ischaemia-reperfusion injury models — characterising reduced cardiomyocyte apoptosis, decreased infarct size, improved left ventricular functional recovery, and attenuation of oxidative stress-induced cell death following PEG MGF treatment. Studies have examined the cardiac MGF signalling mechanisms — characterising PI3K-Akt pro-survival pathway activation, Bcl-2 family anti-apoptotic protein upregulation, mitochondrial membrane potential preservation, and HSP70 stress response induction as components of the cardiomyocyte cytoprotective biology driven by MGF E-domain peptide stimulation. These cardiac biology studies have established PEG MGF as a research tool for studying the cardioprotective biology of locally produced IGF-1 splice variants in cardiac stress and injury contexts.

Neural MGF Biology and Neuroprotection Research

MGF is expressed in brain and spinal cord tissue following mechanical injury and ischaemic insult — and the MGF E-domain peptide produces neuroprotective responses in neurons and neural progenitor cells through mechanisms including anti-apoptotic signalling, oxidative stress resistance, and neural progenitor activation. Research has used PEG MGF in models of traumatic brain injury, spinal cord injury, and neural ischaemia — characterising reduced neuronal apoptosis, enhanced neural progenitor proliferation, attenuated inflammatory responses, and improved functional recovery outcomes following PEG MGF treatment. These neuroprotection studies have established the MGF E-domain peptide as a tissue-protective signalling molecule in neural injury contexts and positioned PEG MGF as a research tool for studying locally produced IGF-1 splice variant biology in the central and peripheral nervous system.

PEGylation Pharmacokinetics and Half-Life Extension Research

PEG MGF serves as a model compound for characterising PEGylation as a half-life extension strategy for short-lived bioactive peptides — enabling research into how PEG chain molecular weight, conjugation site, and conjugation chemistry modify proteolytic stability, renal clearance, tissue distribution, receptor access, and biological activity duration relative to the native unconjugated MGF E-domain peptide. Research has used PEG MGF pharmacokinetic characterisation to examine the relationship between PEG molecular weight and half-life extension magnitude, the extent to which PEGylation modifies MGF E-domain receptor binding kinetics and biological potency, and whether steric shielding from PEG chains reduces on-target receptor engagement as a trade-off against proteolytic stability gains. These PEGylation pharmacokinetics studies have contributed to understanding of PEG-peptide conjugate biology with implications for PEGylation strategy optimisation across therapeutic peptide development.

Comparative MGF E-Domain Versus Full-Length IGF-1 Splice Variant Research

PEG MGF is studied in comparative paradigms alongside full-length MGF, IGF-1Ea, IGF-1Eb, and mature IGF-1 — characterising which aspects of local muscle and tissue repair biology are attributable to the MGF E-domain peptide specifically versus the shared IGF-1 domain common to all splice variants, and establishing the pharmacological boundaries between MGF-specific and IGF-1R-mediated biology in muscle, cardiac, and neural tissue repair contexts. These comparative studies examine satellite cell activation, myoblast proliferation, terminal differentiation kinetics, IGF-1R phosphorylation, and downstream anabolic signalling — establishing how MGF E-domain biology complements, precedes, and differs from the canonical IGF-1-IGF-1R anabolic axis in tissue repair and growth factor research.

What Do Studies Say About PEG MGF?

Satellite Cell Activation and Myoblast Proliferation Driven by MGF E-Domain Documented

Research has documented MGF E-domain peptide-driven satellite cell activation and myoblast proliferative responses in primary satellite cell cultures and in vivo muscle injury models — characterising the transition from quiescent to activated satellite cell states, MyoD upregulation, proliferative burst kinetics, and myoblast pool expansion following MGF E-domain stimulation. PEGylation has been documented to extend these satellite cell activation responses into sustained in vivo tissue exposure windows not achievable with native MGF, enabling chronic satellite cell biology research in intact muscle models.

IGF-1R-Independent Signalling Component of MGF Biology Characterised

Research has characterised an IGF-1R-independent component of MGF E-domain peptide biology in satellite cells and myoblasts — documenting ERK1/2 MAPK activation, calcineurin-NFAT pathway engagement, and proliferative responses that persist in the presence of IGF-1R blockade. These IGF-1R-independent signalling studies have established the MGF E-domain as a pharmacologically distinct entity from mature IGF-1 and contributed to characterisation of the alternative receptor interactions mediating MGF-specific satellite cell biology.

Cardioprotective Biology of MGF E-Domain Documented in Ischaemia Models

Research has documented significant cardioprotective effects of MGF E-domain peptide in rodent cardiac ischaemia-reperfusion models — characterising reduced cardiomyocyte apoptosis, decreased infarct size, PI3K-Akt pro-survival pathway activation, and improved post-ischaemic functional recovery following MGF E-domain peptide treatment. These cardiac biology studies established the MGF E-domain as an endogenous cardioprotective signal whose biology is recapitulated and extended temporally by PEG MGF’s prolonged circulating half-life.

Neuroprotective Effects in Neural Injury Models Documented

Research has documented neuroprotective effects of MGF E-domain peptide in traumatic brain injury and ischaemia models — characterising reduced neuronal apoptosis, neural progenitor activation, and attenuated inflammatory responses. These neuroprotection studies established that MGF E-domain biology extends beyond skeletal and cardiac muscle into the central nervous system and positioned PEG MGF as a research tool for studying the neuroprotective component of locally produced IGF-1 splice variant biology.

PEGylation Half-Life Extension Validated in Pharmacokinetic Studies

Research has validated PEG MGF’s extended circulating half-life relative to native MGF E-domain peptide — documenting dramatically reduced proteolytic degradation in serum stability assays and extended plasma exposure windows in rodent pharmacokinetic studies consistent with PEG-mediated protease shielding and reduced renal clearance. These pharmacokinetic studies established that PEGylation achieves the intended half-life extension for the MGF E-domain without abolishing receptor-active peptide biology.

Muscle Regeneration Outcomes Enhanced by PEG MGF in Injury Models

Research has documented enhanced muscle regeneration outcomes in rodent muscle injury models following PEG MGF administration — characterising accelerated satellite cell activation kinetics, increased regenerating myofibre cross-sectional area, reduced fibrotic tissue deposition, and improved functional force recovery in PEG MGF-treated muscles relative to vehicle controls. These in vivo regeneration studies established PEG MGF as a pharmacological tool for studying sustained MGF E-domain biology in the full muscle repair programme.

How Does PEG MGF Compare to Related IGF-1 Splice Variant and Muscle Repair Research Compounds?

Feature	PEG MGF	Native MGF (Unconjugated)	IGF-1 (Mature)	IGF-1Ea	Insulin	GHRP-6
Type	PEGylated MGF E-domain peptide — long-acting	Native MGF E-domain peptide — short-acting	Mature 70-aa IGF-1 — canonical growth factor	Full-length liver-type IGF-1 splice variant	Pancreatic peptide hormone	Synthetic hexapeptide GHS-R1a agonist
Primary Mechanism	MGF-specific receptor + IGF-1R-independent signalling → satellite cell activation + cytoprotection	Same — short half-life limits in vivo utility	IGF-1R tyrosine kinase → PI3K-Akt + MAPK → anabolic and mitogenic biology	IGF-1R agonism + Ea domain biology	IR and IGF-1R agonism → glucose uptake + anabolic signalling	GHS-R1a agonism → GH release → indirect IGF-1 elevation
Half-Life	~24–72 hours — PEG-dependent	~2–5 minutes — serum protease labile	~10–16 hours (free) / days (IGFBP-bound)	~hours	~5 minutes	~15–60 minutes
Satellite Cell Activation	Direct — primary research application	Direct — in vitro only	Indirect — IGF-1R mediated	IGF-1R mediated	Minimal direct effect	Indirect via GH/IGF-1 axis
IGF-1R Engagement	Partial — IGF-1R-independent component documented	Partial — IGF-1R-independent component	Full canonical IGF-1R agonism	Full canonical IGF-1R agonism	IR primary / IGF-1R secondary	Indirect only
Cardioprotection	Yes — documented	Yes — limited by half-life	Yes — IGF-1R mediated	Yes	Partial — IR-mediated	Yes — GHS-R1a mediated
Neuroprotection	Yes — documented	Limited by half-life	Yes	Yes	Limited	Limited
Anabolic / Mitogenic Biology	Limited — E-domain primary activity	Limited	Pronounced — IGF-1R mediated	Pronounced	Pronounced — IR mediated	Indirect via GH
Key Research Distinction	Long-acting MGF E-domain — in vivo satellite cell activation and tissue repair research	Reference short-acting MGF E-domain — in vitro only	Canonical IGF-1R reference agonist	Systemic IGF-1 splice variant reference	IR/IGF-1R metabolic reference	Reference GHS-R1a agonist — indirect IGF-1

Product Specifications

Parameter	Detail
Name	PEG MGF
Also Designated	PEGylated Mechano Growth Factor / PEG-MGF E-domain peptide / Long-Acting MGF
Type	PEGylated Synthetic MGF C-Terminal E-Domain Peptide — Long-Acting IGF-1 Splice Variant Research Compound — Research Grade
Peptide Sequence	24-amino acid MGF C-terminal E-domain peptide — Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys
PEG Conjugation	Polyethylene glycol chain covalently conjugated to peptide — molecular weight and conjugation site per batch specification
Molecular Weight	Peptide ~2867 Da + PEG chain — total MW per batch CoA
Mechanism	MGF E-domain receptor engagement → ERK1/2 MAPK + calcineurin-NFAT + PI3K-Akt signalling → satellite cell activation + myoblast proliferation + cytoprotective anti-apoptotic biology — IGF-1R-independent component documented
Primary Research Areas	Satellite cell activation / muscle repair and regeneration / MGF-specific receptor pharmacology / IGF-1R-independent signalling / cardiac cytoprotection / neuroprotection / PEGylation pharmacokinetics / comparative IGF-1 splice variant biology
Half-Life	~24–72 hours — PEG chain molecular weight dependent
Key Research Distinction	Only long-acting MGF E-domain research compound — enables in vivo satellite cell activation, chronic tissue repair biology, and sustained MGF receptor pharmacology studies not achievable with native unconjugated MGF
Purity	≥99% HPLC & MS Verified
Form	Sterile Lyophilised Powder
Solubility	Sterile water or sterile PBS pH 7.4 — PEGylation substantially improves aqueous solubility relative to native MGF
Storage (Powder)	-20°C, protect from light and moisture
Storage (Reconstituted)	-80°C in single-use aliquots — minimise freeze-thaw cycles
Manufacturing	GMP Manufactured
Intended Use	Research use only

PEG MGF Reconstitution — Important Note

PEG MGF reconstitutes readily in sterile water or sterile PBS pH 7.4 — the PEG conjugation substantially improves aqueous solubility and reduces aggregation tendency relative to the native unconjugated MGF E-domain peptide. Add reconstitution solvent slowly to the lyophilised powder and swirl gently until fully dissolved — do not vortex as mechanical agitation can promote PEG-peptide conjugate aggregation. The PEG chain provides steric protection against proteolytic degradation in biological matrices but does not protect against chemical degradation under extreme pH conditions — avoid strongly acidic or alkaline reconstitution buffers. For in vitro satellite cell activation and myoblast proliferation assays, prepare working dilutions in serum-free or low-serum assay medium immediately before addition to cell cultures — note that serum-containing media will not substantially degrade PEG MGF due to PEG-mediated protease shielding, allowing longer pre-incubation in serum-containing conditions than would be possible with native MGF. For IGF-1R-independent signalling studies, confirm IGF-1R blockade with validated antibodies or small molecule inhibitors before PEG MGF addition to distinguish MGF-specific from IGF-1R-mediated signalling components. For in vivo muscle repair studies, prepare fresh working solutions in sterile saline at the time of administration. Store reconstituted aliquots at -80°C and avoid repeated freeze-thaw cycles that can degrade PEG-peptide conjugate stability over time.

Buy PEG MGF in Ireland — What’s Included

Every order of PEG MGF in Ireland includes:

✅ Batch-Specific Certificate of Analysis (CoA)

✅ HPLC Chromatogram

✅ Mass Spectrometry Confirmation — including PEG conjugation verification

✅ PEG Chain Molecular Weight Specification

✅ Sterility & Endotoxin Testing Report

✅ Reconstitution Protocol — including PEGylation solubility and in vitro assay guidance

✅ Technical Research Support

Frequently Asked Questions — PEG MGF Ireland

Can I Buy PEG MGF in Ireland?

Yes — research-grade PEG MGF is available to researchers and institutions across Ireland with fast dispatch and full batch documentation. Supplied strictly for laboratory research purposes only.

What Is Mechano Growth Factor and How Does It Differ from IGF-1?

Mechano Growth Factor is produced by mechano-sensitive alternative splicing of the IGF-1 pre-mRNA in muscle, cardiac, and neural tissue following mechanical loading or injury — generating a unique C-terminal E-domain peptide sequence absent from all other IGF-1 splice variants. The MGF E-domain activates IGF-1R-independent signalling pathways and satellite cell responses not produced by mature IGF-1, establishing MGF as a locally produced tissue repair signal pharmacologically distinct from the systemic endocrine IGF-1 axis.

Why Is PEGylation Necessary for In Vivo MGF Research?

Native unconjugated MGF E-domain peptide has a circulating half-life of under 5 minutes due to rapid serum protease degradation — limiting its utility to acute in vitro applications. PEGylation extends half-life to 24–72 hours through steric protease shielding and reduced renal clearance, enabling in vivo tissue exposure studies, chronic satellite cell activation research, and systemic tissue repair biology investigations not achievable with the native peptide.

Does PEG MGF Engage the IGF-1 Receptor?

Research has documented both IGF-1R-dependent and IGF-1R-independent components of MGF E-domain biology. Satellite cell and myoblast responses to MGF E-domain peptide persist partially in the presence of IGF-1R blockade — establishing that the MGF C-terminal domain engages receptor targets distinct from or in addition to IGF-1R. The full receptor pharmacology of the MGF E-domain remains an active research area.

What Controls Are Essential for PEG MGF Research?

Vehicle controls in matched reconstitution buffer, native unconjugated MGF E-domain peptide as a short-acting reference, mature IGF-1 as an IGF-1R reference agonist, IGF-1R blocking antibody or small molecule inhibitor controls to dissect IGF-1R-dependent versus independent signalling components, and scrambled MGF E-domain sequence peptide as a sequence-specificity negative control. For PEGylation pharmacokinetics studies, PEG-only controls confirm absence of PEG chain-intrinsic biological effects.

How Does PEG MGF Differ from IGF-1 LR3 in Research Applications?

IGF-1 LR3 is a long-acting IGF-1 analogue acting through canonical IGF-1R signalling with reduced IGFBP binding — producing anabolic, mitogenic, and metabolic IGF-1R-mediated biology. PEG MGF acts primarily through the MGF E-domain with an IGF-1R-independent signalling component — driving satellite cell activation and tissue repair initiation biology distinct from IGF-1R-mediated anabolic responses. The two compounds address complementary rather than overlapping research questions in IGF-1 axis biology.

What Purity Is Required for PEG MGF Research?

≥99% purity by HPLC and mass spectrometry is essential — unconjugated MGF E-domain peptide impurities, PEG chain heterogeneity beyond specification, and oxidised peptide variants would produce confounded pharmacokinetic and receptor pharmacology data. PEG conjugation verification by mass spectrometry confirming expected molecular weight of the PEG-peptide conjugate is a critical specification beyond standard peptide purity assessment. All PEG MGF Ireland stock is verified to ≥99% purity with PEG conjugation confirmed.

Research Disclaimer

PEG MGF is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. This product is not intended for human consumption, self-administration, or any therapeutic application. It must be handled by qualified researchers in compliance with applicable Irish and EU regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in vitro or pre-clinical research purposes.